J Bollerslev, Section of Specialized Endocrinology, Department of Endocrinology, Medical Clinic, Oslo University Hospital, Oslo, Norway.
L Rejnmark, Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, 8000, Denmark.
Eur J Endocrinol. 2022 Jan 13;186(2):R33-R63. doi: 10.1530/EJE-21-1044. Print 2022 Feb 1.
This European expert consensus statement provides recommendations for the diagnosis and management of primary hyperparathyroidism (PHPT), chronic hypoparathyroidism in adults (HypoPT), and parathyroid disorders in relation to pregnancy and lactation. Specified areas of interest and unmet needs identified by experts at the second ESE Educational Program of Parathyroid Disorders (PARAT) in 2019, were discussed during two virtual workshops in 2021, and subsequently developed by working groups with interest in the specified areas. PHPT is a common endocrine disease. However, its differential diagnosing to familial hypocalciuric hypercalcemia (FHH), the definition and clinical course of normocalcemic PHPT, and the optimal management of its recurrence after surgery represent areas of uncertainty requiring clarifications. HypoPT is an orphan disease characterized by low calcium concentrations due to insufficient PTH secretion, most often secondary to neck surgery. Prevention and prediction of surgical injury to the parathyroid glands are essential to limit the disease-related burden. Long-term treatment modalities including the place for PTH replacement therapy and the optimal biochemical monitoring and imaging surveillance for complications to treatment in chronic HypoPT, need to be refined. The physiological changes in calcium metabolism occurring during pregnancy and lactation modify the clinical presentation and management of parathyroid disorders in these periods of life. Modern interdisciplinary approaches to PHPT and HypoPT in pregnant and lactating women and their newborns children are proposed. The recommendations on clinical management presented here will serve as background for further educational material aimed for a broader clinical audience, and were developed with focus on endocrinologists in training.
本欧洲专家共识声明就原发性甲状旁腺功能亢进症(PHPT)、成人慢性甲状旁腺功能减退症(HypoPT)以及与妊娠和哺乳期相关的甲状旁腺疾病的诊断和管理提供了建议。在 2019 年第二次甲状旁腺疾病(PARAT)ESE 教育计划中,专家们确定了特定的关注领域和未满足的需求,这些需求在 2021 年的两次虚拟研讨会上进行了讨论,并随后由对特定领域感兴趣的工作组制定。PHPT 是一种常见的内分泌疾病。然而,其与家族性低钙血症高钙血症(FHH)的鉴别诊断、血钙正常 PHPT 的定义和临床病程,以及手术后复发的最佳管理,这些方面都存在不确定性,需要进一步澄清。HypoPT 是一种孤儿病,其特征是由于 PTH 分泌不足导致血钙浓度降低,这种情况最常继发于颈部手术。预防和预测甲状旁腺手术损伤对于限制疾病相关负担至关重要。长期治疗方式,包括 PTH 替代治疗的位置以及慢性 HypoPT 治疗相关并发症的最佳生化监测和影像学监测,需要进一步完善。钙代谢在妊娠和哺乳期发生的生理变化会改变这些时期甲状旁腺疾病的临床表现和管理。本共识还提出了针对妊娠和哺乳期妇女及其新生儿儿童的 PHPT 和 HypoPT 的现代跨学科方法。这里提出的临床管理建议将作为针对更广泛临床受众的进一步教育材料的背景,并且重点关注接受培训的内分泌学家。